Compare CDLX & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | ELUT |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3M | 45.8M |
| IPO Year | 2018 | 2020 |
| Metric | CDLX | ELUT |
|---|---|---|
| Price | $0.88 | $1.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.25 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.7M | 111.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.13 | ★ 146.77 |
| EPS | N/A | ★ 0.87 |
| Revenue | ★ $233,273,000.00 | $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.82 | $10.83 |
| P/E Ratio | ★ N/A | $1.30 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.67 | $0.50 |
| 52 Week High | $3.28 | $2.60 |
| Indicator | CDLX | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 52.46 |
| Support Level | $0.88 | $1.00 |
| Resistance Level | $1.11 | $1.16 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 4.11 | 61.11 |
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.